2026-06-14T05:06:17Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/102542025-06-09T10:40:42Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Nguyen, L T T author Roman, Federico author Morikawa, K author Trincado, Pilar author Marcos-Moreno, Maria del Carmen author Rojo-Martín, M D author Cafini, F author 2018 As a consequence of the dissemination of methicillin-resistant Staphylococcus aureus (MRSA) strains and the accumulation of several resistant traits, only a few antibiotics such as vancomycin or linezolid are considered as the last resort antibiotics for the treatment of these strains. The finding of a transferable chloramphenicol/florphenicol resistance (cfr) gene, related to linezolid resistance, has compromised the usage of this antimicrobial in the clinical practice. Although the prevalence of MRSA strains showing resistance to linezolid is still low, hospital outbreaks due to cfr-positive MRSA strains have been documented in Spain [1]. Int J Antimicrob Agents. 2018 Aug;52(2):305-306 10.1016/j.ijantimicag.2018.06.004 1872-7913 0924-8579 International journal of antimicrobial agents 29898410 http://hdl.handle.net/20.500.12105/10254 Prevalence of pSCFS7-like vectors among cfr-positive staphylococcal population in Spain